Lokelma

Lokelma Dosage/Direction for Use

sodium zirconium cyclosilicate

Manufacturer:

AstraZeneca

Distributor:

Zuellig
/
Four Star
The information highlighted (if any) are the most recent updates for this brand.
Full Prescribing Info
Dosage/Direction for Use
Posology: Lokelma should not replace emergency treatment for life threatening hyperkalaemia. Lokelma starts to reduce serum potassium 1 hour after administration in patients with hyperkalaemia.
Adults, including the elderly: Correction phase: The recommended starting dose of Lokelma is 10 g, administered three times a day orally as a suspension in water. When normokalaemia is achieved, the maintenance regimen should be followed (see Maintenance phase as follows).
Typically, normokalaemia is achieved within 24 to 48 hours. If patients are still hyperkalaemic after 48 hours of treatment, the same regimen can be continued for an additional 24 hours. If normokalaemia is not achieved after 72 hours of treatment, other treatment approaches should be considered.
Maintenance phase: When normokalaemia has been achieved, the minimal effective dose of Lokelma to prevent recurrence of hyperkalaemia should be established. A starting dose of 5 g once daily is recommended, with possible titration up to 10 g once daily, or down to 5 g once every other day, as needed, to maintain a normal potassium level. No more than 10 g once daily should be used for maintenance therapy.
Serum potassium levels should be monitored regularly during treatment. Monitoring frequency will depend upon a variety of factors including other medications, progression of chronic kidney disease and dietary potassium intake.
If severe hypokalaemia should occur, Lokelma should be discontinued and the patient re-evaluated.
Missed dose: If a patient misses a dose they should be instructed to take the next usual dose at their normal time.
Special populations: Patients with renal/hepatic impairment: No changes from the normal doses are required for patients with renal or hepatic impairment.
Paediatric population: The safety and efficacy of Lokelma in children and adolescents (< 18 years) have not been established. No data are available.
Method of administration: For oral use.
The entire contents of the sachet should be emptied in a drinking glass containing approximately 45 ml of water and stirred well. The powder will not dissolve. The tasteless liquid should be drunk while still cloudy. If the powder settles, the water should be stirred again. It should be ensured that all of the content is taken.
The suspension can be taken with or without food.
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Already a member? Sign in
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Already a member? Sign in